https://www.selleckchem.com/products/dx3-213b.html
8 ± 2.9) to FUV1 (5.1 ± 3.4; p less then 0.001) and FUV2 (5.5 ± 3.2; p less then 0.001). The percentage of patients exhibiting freezing, dystonia, gait/walking disturbances, falls, pain and sleep disorders was significantly reduced. Twenty-eight device complications were reported and 11 (6.9%) patients prematurely terminated the study. LCIG after 12-month treatment led to sustained improvement of time spent in "OFF", complications of therapy, PD-associated symptoms and sleep disorders. LCIG tolerability was consistent with the esta
Like
Comment
Share
